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Retinoblastoma (Rb) is a pediatric intraocular malignancy and
probably the most robust clinical model on which genetic predis-
position to develop cancer has been demonstrated. Since deletions
in chromosome 13 have been described in this tumor, we per-
formed next generation sequencing to test whether recurrent losses
could be detected in low coverage data. We used Illumina platform
for 13 tumor tissue samples: two pools of 4 retinoblastoma cases
each and one pool of 5 medulloblastoma cases (raw data can be
found at http://www.ebi.ac.uk/ena/data/view/PRJEB6630).
We ﬁrst created an in silico reference proﬁle generated from avier Inc. This is an open access article under the CC BY license
/j.cancergen.2015.12.001
ce-Castañeda).
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A.J. García-Chequer et al. / Data in Brief 6 (2016) 908–916 909human sequenced genome (GRCh37p5). From this data we calcu-
lated an integrity score to get an overview of gains and losses in all
chromosomes; we next analyzed each chromosome in windows of
40 kb length, calculating for each window the log2 ratio between
reads from tumor pool and in silico reference. Finally we generated
panoramic maps with all the windows whether lost or gained along
each chromosome associated to its cytogenetic bands to facilitate
interpretation. Expression microarrays was done for the same
samples and a list of over and under expressed genes is presented
here. For this detection a signiﬁcance analysis was done and a log2
fold change was chosen as signiﬁcant (raw data can be found at
http://www.ncbi.nlm.nih.gov/geo/accession number GSE11488). The
complete research article can be found at Cancer Genetics journal
(Garcia-Chequer et al., in press) [1]. In summary here we provide an
overview with visual graphics of gains and losses chromosome by
chromosome in retinoblastoma and medulloblastoma, also the
integrity score analysis and a list of genes with relevant expression
associated. This material can be useful to researchers that may want
to explore gains and losses in other malignant tumors with this
approach or compare their data with retinoblastoma.
& 2016 The Authors. Published by Elsevier Inc. This is an open access
article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).Speciﬁcations Tableubject area Biomedicine, Bioinformatics
ore speciﬁc sub-
ject areaHuman Genomics of retinoblastoma and medulloblastoma.ype of data Tables, graphs, chromosome maps and ﬁgures
rganism/cell line/
tissueHuman, retinoblastoma and medulloblastoma primary tissuesow data was
acquiredDNA was isolated from snap frozen pediatric tumors (retinoblastoma and
medulloblastoma), DNA was pooled and sequenced using an Illumina Gen-
ome Analyzer IIX. Expression microarray data was generated with RNA iso-
lated from the corresponding short term primary cultures and analyzed with
an in house two channel platform of expression microarrays and using as a
reference RNA isolated from S. cerevisiae harvested at log phase growth.ata format Raw sequencing data, analyzed data and mapped data
xperimental
factors2 retinoblastoma pools (2 boys and 2 girls each one)
1 medulloblastoma pool (4 boys and 1 girl)
All patients were naïve to chemotherapy treatment at the moment of the
sample collection.xperimental
featuresRetinoblastoma and medulloblastoma tissues samples were deep sequenced
in 3 pools (2 Rb and 1 Mb). The sequencing data was ﬁltered, mapped using
an in silico reference and analyzed chromosome by chromosome to evaluate
their integrity and to ponder important regions of gains or losses at the
chromosomes.onsent All tumor tissues were collected under informed written consent from the
patients’ parents and as part of studies approved by the Scientiﬁc and Ethics
Review Boards from each participating institution.ata source
locationMexico city, Hospital de Pediatría, Centro Médico Nacional Siglo XXI, IMSS
and Mexico city, Hospital Infantil de México, SS.
DA.J. García-Chequer et al. / Data in Brief 6 (2016) 908–916910ata accessibility Deposited raw data of the NGS of retinoblastoma and meduloblastoma can
be found at: http://www.ebi.ac.uk/ena/data/view/PRJEB6630.
Microarray Data sets are uploaded at GEO-NCBI database in: http://www.
ncbi.nlm.nih.gov/geo/ accession number GSE11488.Value of the data Retinoblastoma tissues naïve to treatment are very rare and scarce and thus difﬁcult to obtain
and study.
 With the visual graphics presented, the data provides an overview of the retinoblastoma and
medulloblastoma genomes structure easy to comprehend, analyze and compare.
 This data facilitates the merge of cytogenetic information and vocabulary with next generation
sequencing information and vocabulary.
 The format of data presentation with the pooling experimental design facilitates navigation
through complex data, allowing exploration of recurrent events in an intuitive manner.
 Simplicity of these analyses can guide researchers about interesting genomic areas of consistent
recurrent losses for further study in these genomes.
 The data can help in the design of future analysis like cytogenetics, selecting genes to study by
immunohistochemistry, gene hunting etc.
 The data can help to easily compare chromosomal changes with other type of tumors.1. Data
Next generation sequencing was done for retinoblastoma and medulloblastoma samples. These
sequences or “reads” were mapped and compared to a human reference genome and low coverage
was determined. This comparison allowed the construction of chromosomal maps with positions and
association to cytogenetic bands for an overview of the data. An integrity score was used for a
panoramic view of the sequencing data. Expression microarray was also done for the same samples
and lists of over and under expressed genes are presented related to regions of gains and losses [1].2. Experimental design
Tumor tissue samples from 8 retinoblastoma patients and from 5 medulloblastoma patients were
collected. These 13 samples were deep sequenced as three pools, two for retinoblastoma and one for
medulloblastoma. The in silico references were generated from a whole human genome sequence
GRCh37p5 from the Genome Reference Consortium.3. Materials and methods
3.1. Patients and DNA extraction
Eight patients diagnosed with retinoblastoma (Rb) and ﬁve with medulloblastoma (Mb) were
included. DNA was isolated from snap frozen tumor tissues. Two DNA pools from four Rb patients
each were considered biological replicas and one DNA pool containing ﬁve Mb patients considered a
biological contrast were sequenced. The original and raw data are uploaded at the European
Nucleotide Archive and can be found in http://www.ebi.ac.uk/ena/data/view/PRJEB6630.
A.J. García-Chequer et al. / Data in Brief 6 (2016) 908–916 911All patients were newly diagnosed and tumor samples were collected at time of surgery, prior to
any adjuvant therapy. Tumor tissues were collected under informed written consent from their
parents and as part of studies approved by the Scientiﬁc and Ethics Review Boards from each par-
ticipating institution.3.2. Illumina sequencing
Sequencing was performed at the sequencing core facility of the National University of Mexico
(UNAM) located at the Biotechnology Institute in Cuernavaca, Mexico using the Illumina Genome
Analyzer IIx (Illumina). For sequencing 5 mg of DNA, 1.2 μg DNA from each retinoblastoma per pool,
and 1 mg DNA from each meduloblastoma per pool were used to make approximately two hundred
base-pair sized libraries using Illumina’s Genomic DNA sample prep kit.3.3. In silico genome references
A reference proﬁle of sequencing data for each sample was obtained using an in silico technique.
The whole human genome sequence GRCh37p5 was downloaded from the Genome Reference
Consortium.Fig. 1. Integrity score for all the samples including ChrY. Each plot corresponds to each one of the samples, in the left the
references and in the right the tumors. The points in the plots represent the human chromosomes. Chromosome Y is an outlier
indicated by the arrow in all the samples.
A.J. García-Chequer et al. / Data in Brief 6 (2016) 908–916912A random sampling of this reference genome was done for the generation of reference sets
of reads.3.4. Reads mapping and symmetric relation treatment
The treatment applied to both sequencing datasets and in silico datasets was the same. After ﬁl-
tering out low quality and low complexity reads, both in silico and experimental sets were then
mapped to the GRCh37.p5 genome sequence with Bowtie2 [2]. A Perl program was written for
extracting the reads that map only once to the Human Genome. For the comparison between the in
silico reads and in vitro reads already mapped, log2 ratios values were used.
log ratio¼ log2
Number of reads in Sample X
Number of reads in Referece X
The log2 ratio gives a symmetric relation between two sets of values facilitating the interpretation
of the data. For example, a 2 value will be equivalent to a 2, that will correspond to a relation of 4:1
and 1:4 respectively or a fold change of 4.Fig. 2. Integrity score for all the samples not including ChrY. Each plot corresponds to each one of the samples, in the left the
references and in the right the tumors. The points in the plots represent the human chromosomes.
Fig. 3. Integrity score plotted as bars. Each bar corresponds to each chromosome and this ﬁgure shows a marked difference for
chromosome Y.
Table 1
Shared gross losses between retinoblastoma and medulloblastoma.
Chromosome Cytogenetic band Loss location Genes
(loss size)
Chr 5 q13.2 68.5 M–71 M 66
(2.5 M)
Chr 6 p22.1 28.4M–33.4 M 407
p21.33 (5 M)
p21.32
Chr 17 q21.31 44.1 M–44.6 M 28
(560 K)
Chr 19 p13.11 20 M–22.5 M 103
(2.5 M)
Chr 19 q13.42 54.5 M–55.5 M 66
(1.04 M)
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ChromDraw.exe is a computational program that draws each chromosome and all its cytogenetic
bands. This graphic visualization software was written by one of the authors of the present work
(Méndez-Tenorio, PhD) with the purpose of facilitating identiﬁcation of losses and gains in each
chromosome by analyzing the comparison between one sample and a reference using the log2 ratio
value. This software is available upon request.
Table 2
Over and underexpressed genes in retinoblastoma samples.
CHR Number of over-
expressed genes
Symbol log fold
change
Number of under-
expressed genes
Symbol log fold
change
chr1 6 CSF3R 2.98 2 LOC376745 2.59
CDC42BPA 2.55 DDX20 2.73
FLJ20277 2.33
TRIM17 2.32
KIAA0663 2.27
WARP 2.26
chr2 3 ZFHX1B 3.51 2 ANXA4 2.68
SEMA4F 2.96 TLK1 2.71
C2orf24 2.14
chr3 5 FSTL1 2.83 0
SYN2 2.77
CCR1 2.28
BAP1 2.12
ZFYVE20 2.10
chr4 5 FGFR3 2.43 1 FABP2 2.61
MXD4 2.40
STK32B 2.35
MAD2L1 2.20
LIM 2.12
chr5 0 2 SNX2 2.79
PCSK1 2.86
chr6 4 CUL7 2.75 6 AMD1 2.13
APOBEC2 2.70 TPMT 2.33
RXRB 2.52 BF 2.48
C6orf108 2.27 PGC 2.53
HIST1H1C 2.74
GOPC 3.38
chr7 1 FLJ20359 2.77 2 ORC5L 2.76
ARP3BETA 3.53
chr8 2 FLJ14299 2.84 2 IMPA1 2.70
LY6E 2.49 TNFRSF10A 2.73
chr9 2 SARDH 2.63 2 C9orf78 2.54
GTF3C4 2.40 SMARCA2 3.08
chr10 3 GDF2 2.36 2 SEC23IP 2.20
CCDC6 2.20 ACADSB 2.67
LIPA 2.13
chr11 5 VEGFB 2.89 1 FLJ22794 2.71
ZBTB3 2.76
TIMM10 2.56
DKK3 2.42
MTA2 2.24
chr12 7 NM_002261 3.30 3 ATP5B 2.33
NAB2 2.98 ING4 2.63
DKFZP586A0522 2.85 HCFC2 2.87
NM_025247 2.50
NM_014830 2.47
OAS1 2.42
OAS1 2.35
chr13 0 0
chr14 1 NKX28 2.75 0
chr15 3 SMAD3 2.99 0
B7H3 2.62
FOXB1 2.34
chr16 4 ALDOA 2.92 5 TRAP1 2.33
MT3 2.80 MRTF-B 2.36
SLC12A4 2.75 HMOX2 2.39
TRADD 2.46 KIAA0174 2.47
chr17 7 FLJ11164 3.26 2 CCL7 2.48
HOXB4 3.01 TBCD 2.61
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Table 2 (continued )
CHR Number of over-
expressed genes
Symbol log fold
change
Number of under-
expressed genes
Symbol log fold
change
TOP3A 2.91
DKFZp434H2215 2.64
FLJ10385 2.62
MGC4172 2.54
MEOX1 2.24
chr18 0 0
chr19 13 SNAPC2 3.07 4 FLJ11535 2.22
TBXA2R 3.04 POLD1 2.39
P2RY11 3.00 ASNA1 3.45
MGC3169 2.86 GAPDS 4.16
AURKC 2.69
CEACAM3 2.56
ZNF42 2.37
EFNA2 2.36
VMD2L1 2.30
EPOR 2.27
MRPL4 2.26
KLF2 2.25
IL12RB1 2.08
chr20 2 GNRH2 4.23 0
GPR8 3.12
chr21 1 NDUFV3 2.86 1 CLDN17 2.90
chr22 2 SUSD2 2.84 3 TOM1 2.11
XBP1 2.61 PSCD4 2.24
chrX 1 CTAG1B 2.58 2 HEPH 2.42
DKC1 2.50
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The integrity score was calculated as a relation between the number of reads in a chromosome and
the length of that chromosome, in units of reads/kilobase. The integrity score allow us an overview of
losses and gains in all the chromosomes. This score is calculated as follows:
Score Chri¼ Number of reads in chromosome i
Length of chromosome i
½ ¼  reads
kB
With this score is possible to explore linearity of sequencing and in silico data by plotting the size
of each chromosome in millions of bp against the number of reads obtained for each chromosome.
Because we found a linear relationship between ﬁltered reads and chromosome size we developed
the integrity score. Using this integrity score is possible to determine with low resolution if there is
any chromosome with less or more reads compared to its reference. The integrity score was calcu-
lated for all the chromosomes in the six data samples, three for the reference samples and three for
the pooled tumor samples. Figs. 1 and 2 show the plot for all the references and samples considering
or not the Chromosome Y respectively. The r2 value can be seen in each individual plot. Another ﬁgure
shows the Integrity Score plotted as bars and a marked difference for chromosome Y is observed in all
tumors and reference samples (Fig. 3).
3.7. Chromosomes analyses by windows
Each chromosome sequence was divided into fragments of the same length (40 kb) called ‘win-
dows’. Mapped reads in each window for both the in silico reference and the tumor samples were
A.J. García-Chequer et al. / Data in Brief 6 (2016) 908–916916measured and using ChromDraw data is plotted as logg ratios against the cytogenetic maps (See
Supplemental Maps File) (Table 1).
3.8. Expression microarrays
Expression microarray data was generated at the microarray facility of the National University of
Mexico (UNAM) located at the Instituto de Fisiología Celular in Mexico City. Total RNA was obtained
using Trizol reagent by Ambion according to manufacturer directions, from short term primary cul-
tures established from enucleated eyes and propagated for seven days in RPMI 15% FBS. In house
double channel platform was used and microarrays were printed with a human 50-mer oligo library
set “A” from MWG BiotechOligo Gene expression was determined as signiﬁcant over or under
expressed using the Signiﬁcance Analysis of Microarray (SAM) algorithm from the TM4 suite of
programs [3]. A log fold change value larger than 2 or lower than -2 was used for selecting the over
and under expresses genes respectively and a false discovery rate of 0.05 [4]. A list with the over and
under expressed genes is shown in Table 2.Acknowledgments
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